TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response

Journal of Neuroimmunology

Volumn 190, Issue 1-2, 2007, Pages 170-176

  Buttmann, Mathias ^a   Merzyn, Cornelia ^a   Hofstetter, Harald H ^a,b   Rieckmann, Peter ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adverse effects; Biological markers; CXC chemokine IP 10; Interferon beta; Monocyte chemoattractant protein 1; Multiple sclerosis; TNF related apoptosis inducing ligand

Indexed keywords

BETA1A INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; INTERFERON BETA SERINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; HUMAN; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION;

ADULT; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINE CXCL10; FEMALE; HUMANS; INFLUENZA, HUMAN; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 35448988455     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.08.009     Document Type: Article

References (35)

1. Aktas O., Smorodchenko A., Brocke S., Infante-Duarte C., Topphoff U.S., Vogt J., Prozorovski T., Meier S., Osmanova V., Pohl E., Bechmann I., Nitsch R., and Zipp F. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (2005) 421-432
2. Arbour N., Rastikerdar E., McCrea E., Lapierre Y., Dörr J., Bar-Or A., and Antel J.P. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult. Scler. 11 (2005) 652-657
3. Ashkenazi A., and Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11 (1999) 255-260
4. Buttmann M., Berberich-Siebelt F., Serfling E., and Rieckmann P. Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J. Vasc. Res. 44 (2007) 51-60
5. Buttmann M., Goebeler M., Toksoy A., Schmid S., Graf W., Berberich-Siebelt F., and Rieckmann P. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J. Neuroimmunol. 168 (2005) 175-182
6. Buttmann M., Merzyn C., and Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J. Neuroimmunol. 156 (2004) 195-203
7. Choi E.A., Lei H., Maron D.J., Wilson J.M., Barsoum J., Fraker D.L., El-Deiry W.S., and Spitz F.R. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 63 (2003) 5299-5307
8. Chou A.H., Tsai H.F., Lin L.L., Hsieh S.L., Hsu P.I., and Hsu P.N. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J. Immunol. 167 (2001) 1347-1352
9. Clarke N., Jimenez-Lara A.M., Voltz E., and Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23 (2004) 3051-3060
10. Comabella M., Imitola J., Weiner H.L., and Khoury S.J. Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J. Neuroimmunol. 126 (2002) 205-212
11. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
12. Cretney E., McQualter J.L., Kayagaki N., Yagita H., Bernard C.C., Grewal I.S., Ashkenazi A., and Smyth M.J. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol. Cell Biol. 83 (2005) 511-519
13. Di Pietro R., and Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J. Cell. Physiol. 201 (2004) 331-340
14. Galimberti D., Bresolin N., and Scarpini E. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Rev. Neurother. 4 (2004) 439-453
15. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
16. Goodin D.S. Treatment of multiple sclerosis with human beta interferon. Int. MS J. 12 (2005) 96-108
17. Hilliard B., Wilmen A., Seidel C., Liu T.S., Goke R., and Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 1314-1319
18. Hirata S., Senju S., Matsuyoshi H., Fukuma D., Uemura Y., and Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J. Immunol. 174 (2005) 1888-1897
19. Huang W.X., Huang M.P., Gomes M.A., and Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55 (2000) 928-934
20. Jurewicz A., Matysiak M., Andrzejak S., and Selmaj K. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia 53 (2006) 158-166
21. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 (1999) 1451-1460
22. Lünemann J.D., Waiczies S., Ehrlich S., Wendling U., Seeger B., Kamradt T., and Zipp F. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168 (2002) 4881-4888
23. Marsters S.A., Pitti R.M., Donahue C.J., Ruppert S., Bauer K.D., and Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6 (1996) 750-752
24. Matysiak M., Jurewicz A., Jaskolski D., and Selmaj K. TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125 (2002) 2469-2480
25. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
26. Salmon P., Le Cotonnec J.Y., Galazka A., Abdul-Ahad A., and Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16 (1996) 759-764
27. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., Yagita H., Okumura K., Tanaka N., Taniguchi T., and Ogasawara K. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31 (2001) 3138-3146
28. Satoh J., Nakanishi M., Koike F., Miyake S., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Kanda T., Fukazawa T., and Yamamura T. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 18, (2005) 537-550
29. Satoh J., Nanri Y., Tabunoki H., and Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol. 6 (2006) 18
30. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., Hilliard B., and Chen Y. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191 (2000) 1095-1104
31. Sørensen T.L., Sellebjerg F., Jensen C.V., Strieter R.M., and Ransohoff R.M. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur. J. Neurol. 8 (2001) 665-672
32. Wandinger K.P., Lünemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundström E., Ehrlich S., Wernecke K.D., Volk H.D., and Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (2003) 2036-2043
33. Wandinger K.P., Stürzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., and Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50 (2001) 349-357
34. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
35. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 59 (2002) 802-808